Ocugen is a clinical-stage biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Co. develops, manufactures, and commercializes COVAXIN for the prevention of COVID-19. Co.'s gene therapy candidate, OCU400 is for the treatment of certain disease genotypes: nuclear receptor subfamily 2 group E member 3, centrosomal protein 290, rhodopsin, and phosphodiesterase 6B mutation-associated inherited retinal degenerations. Co.'s second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A for the treatment of dry age-related macular degeneration. We show 19 historical shares outstanding datapoints in our coverage of OCGN's shares outstanding history.
Understanding the changing numbers of OCGN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like OCGN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching OCGN by allowing them to research OCGN shares outstanding history
as well as any other stock in our coverage universe. |
Free OCGN Email Alerts:
Video: Shares Outstanding Importance
